MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
Posted on: Friday, 23 January 2009, 09:08 CST
The first report, entitled "Thought Leader Insight & Analysis - AML/MDS," focuses on acute myelogenous leukemia and myelodysplastic syndrome. "This report highlights the most important data presented at ASH, and clarifies the ways these data will change clinical practice," according to
The second report, entitled "Thought Leader Insight & Analysis - Multiple Myeloma/Lymphoma," focuses on how the clinical data presented at ASH is likely to translate into changing treatment paradigms. "This report brings together the diverse perspectives of experts who grapple with a wide spectrum of issues related to these hematologic malignancies, including clinical pathology, community based patients, tertiary care treatment, and medical oncology from the strategic vantage point of clinical commercial development," said Berk.
Topics this report addresses include:
-- Reimbursement: oral vs. parenteral; induction vs. maintenance. -- Multiple myeloma/lymphoma treatment strategies, including: - transplant eligible/non-transplant eligible; - induction/maintenance; - doublets/triplets; - community/tertiary care; - +65 years old/younger; and - approval pathways.Companies mentioned in these reports include: Allos, Amgen, Bayer-Schering, Biogen Idec, BMS (Kosan), Celgene, Cell Therapeutics, Cephalon, Eisai, Genentech, Genmab, Genzyme, Geron, GSK,
This report can be purchased by contacting MedPredict (www.medpredict.com).
About MedPredict
MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
SOURCE MedPredict
Source: PR Newswire
Related Articles
- American Lung Association Urges Full Coverage of Clinically Proven Smoking Cessation Treatments
- Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
- CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting With FDA
- Transport Reports Progress in Treatment of Herpes Labialis
- Medarex Announces Initiation of Phase I Clinical Trial for the Treatment of Psoriasis
- Nutra Pharma Announces Final Approval to Begin Phase IIb Human Clinical Trial for the Treatment of Adrenomyeloneuropathy
- Positive Results From Phase 3 Clinical Study of Methylnaltrexone Treatment for Opioid-Induced Constipation Presented at Digestive Disease Week Conference
- Medarex Announces Start of Dosing in Phase I Clinical Trial for the Treatment of Lupus
- REVLIMID(R) Clinical Results As Oral Treatment Regimen in Newly Diagnosed Multiple Myeloma Presented at the 47th American Society of Hematology Meeting
- The Most Prevalent and Costly Diseases in the U.S. Detailed in a New Disease Incidence and Prevalence Report Published By Medtech Insight
 |
 |
User Comments (0)
RSS Feeds